PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 11121665

Real-time optimized intraoperative dosimetry for prostate brachytherapy: a pilot study.

D C Beyer·R H Shapiro·F Puente
View original source ↗Export metadata ↓

Abstract

PURPOSE: To assess the feasibility of real-time intraoperative treatment planning for permanent prostate brachytherapy analyzing the impact on operative time and adequacy of postimplant dosimetry. METHODS AND MATERIALS: Seventeen consecutive patients undergoing permanent brachytherapy for prostate cancer had real-time intraoperative computer-based and optimized treatment planning. The first 8 patients were implanted using a plan generated before the surgery and served to assure the team qualitatively that this could be performed without greatly increasing intraoperative time. They served as control group for expected achieved dosimetry results reviewing the D90, V100, V150 parameters from the dose-volume histograms. The next 9 patients were implanted according to the real-time plan. The times needed to carry out various steps of the procedure were recorded. The achieved dosimetry was then compared to the control group to assure that accuracy was unchanged. RESULTS: The median operative time for patients undergoing intraoperative dosimetry was 57 min. Of this, 21 min were devoted to anesthesia and nursing functions. Postoperative dosimetry showed a median achieved V100 (volume of prostate receiving 100% of prescribed dose) of 97% for the control group. For the real-time dosimetry group, the median V100 was similar at 94%. The V150 (volume receiving 150%) is 49% for both groups. The D90 (dose received by 90% of the target) was normalized for easy comparison and was consistently slightly greater than the prescription dose. CONCLUSION: Treatment planning for permanent brachytherapy of prostate cancer has historically been performed as a computer-generated and optimized plan run weeks in advance of an implant, or according to a set pattern using an intraoperative nomogram. These data show that planning can now be optimized intraoperatively using widely available software without compromising the operative time or implant quality.

Explore related subjects

Combined Modality TherapyFeasibility StudiesHumansIntraoperative PeriodMalePilot ProjectsProstatic NeoplasmsRadiotherapy DosageRadiotherapy Planning, Computer-AssistedTime FactorsTomography, X-Ray ComputedUltrasonographyJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

D C Beyer, R H Shapiro, F Puente. 2000-12-01. Real-time optimized intraoperative dosimetry for prostate brachytherapy: a pilot study.. https://doi.org/10.1016/s0360-3016(00)01363-8

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

[Fibromyalgia. Diagnostics--disease approach--therapy].

Fibromyalgia is a complex of symptoms predominantly affecting females and consisting of widespread pain. Etiology and pathogenesis are not sufficiently known yet, however, there is the assumption that fibromyalgia is looked at as being an illness with biological, psychological, and social aspects. Therefore, the treatment of fibromyalgia calls for a multimodal therapy approach. The importance of fibromyalgia has been recognized within the German health system by creating the new ICD code M79.70 and by assigning fibromyalgia its own rheumatologic DRG (I79Z). In future research of fibromyalgia special attention needs to be placed upon gender-specific problems.

Combined Modality Therapy↗
PubMed2007

Lack of survival benefit of post-operative radiation therapy in prostate cancer patients with positive lymph nodes.

Randomized data from SWOG 8794 and EORTC 22911 confirm the benefit of post-operative radiation therapy (RT) for selected patients with pT3 prostate cancer (CaP) after radical prostatectomy (RP). However, data regarding the potential benefit of RT for patients post-RP with positive lymph node (+LN) involvement are limited. We analyzed the Surveillance Epidemiology End Results (SEER) registry for population-based data on efficacy of post-operative RT for +LN patients after RP. As LN data have only been captured by SEER since 1988, we analyzed data for 1988-1992, with specific attention to 10-year relative survival (defined as observed survival divided by the survival of a gender-, age- and race-matched population cohort without disease). Specifically analyzed were data for 1921 patients with nonmetastatic prostate cancer who underwent surgery alone, or surgery followed by RT, and who had +LNs documented. SEER does not code the interval between surgery and RT, so the ratio of patients receiving salvage versus adjuvant therapy is unknown. Using follow-up data through 2002, post-diagnosis survival was examined by number of +LNs. There was no significant relative survival benefit for +LN patients receiving post-operative RT (chi(2)P=0.270). These data do not support routine use of post-operative RT for patients with +LNs in the surgical specimen.

Combined Modality Therapy↗